CJC-1295 (NO DAC) 5mg

CJC‑1295 — Overview

CJC‑1295 is a synthetic analog of growth hormone–releasing hormone (GHRH) developed to stimulate endogenous growth hormone (GH) production. It is widely studied in laboratory settings for its role in pituitary signaling, growth hormone regulation, and peptide pharmacokinetics.

Key Research Characteristics

• Peptide Class: GHRH analog
• Structure: 30 amino acids with strategic substitutions
• Variants:
  • CJC‑1295 with DAC (Drug Affinity Complex) — extended half-life via albumin binding
  • CJC‑1295 without DAC — shorter half-life, more frequent dosing
• Mechanism: Stimulates GH release via GHRH receptor activation
• Half-Life:
  • With DAC: ~6–8 days
  • Without DAC: ~30 minutes

Research Applications

CJC‑1295 is commonly studied in contexts involving:

• Growth hormone deficiency models
• Endocrine system modulation
• Sleep and circadian rhythm studies
• Anti-aging and regenerative research
• IGF‑1 secretion dynamics
• Peptide stacking protocols (e.g., with Ipamorelin)

Form & Handling

• Form: Lyophilized powder
• Solubility: Reconstituted in sterile, research-grade solvents
• Storage: Cool, dry environment; protect from light
• Purity: Typically ≥99% for lab-grade use

For laboratory research only. Not for human consumption.